Popular on PrZen
- Thunderbird F-16 Arrives 11/11 - 707
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports - 613
- Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 599
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX - 588
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 575
- Hannk And Zubie Join Forces To Shape The Next Generation Of Connected Vehicle Telematics - 559
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 547
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 545
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids - 533
- "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026 - 522
Similar on PrZen
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
Vein Guardian Introduces Patented Passive Magnetic Concept for Vein Stabilization
PrZen/33626336
Innovative medical device concept designed to support vein stabilization during injections, IV access, and blood collection is available for licensing.
CHICAGO - PrZen -- Axis International Marketing is introducing Vein Guardian, a patented passive magnetic vein stabilizer concept designed to help address challenges associated with vein movement during injections and vascular access procedures.
Vein Guardian incorporates two opposing C-arc magnets positioned along either side of a target vein. The same-polarity magnets are intended to create a repulsive magnetic field that helps stabilize the vein while maintaining an open center for visibility and needle access.
The invention is designed to operate without batteries, charging, or external power. Its adjustable straps and reusable configuration are intended to provide a practical, compact solution for a variety of potential healthcare applications.
Designed for Home and Clinical Applications
As healthcare delivery continues to expand beyond traditional clinical environments, medical device developers are exploring technologies that may support greater patient independence and simplify certain procedures.
Vein Guardian is intended for potential applications involving home self-injection, hospital and clinical IV access, and blood collection in laboratory settings.
The invention's open-center design is intended to allow healthcare professionals and appropriately trained users to locate and access the target vein without removing the device.
A Growing Healthcare Market
According to Mordor Intelligence, the global injectable drug delivery devices market is projected to grow from approximately $810 billion in 2026 to $1.20 trillion by 2031. This broader market includes a wide range of injection technologies and reflects growing interest in home-based healthcare and self-administration.
Vein Guardian represents a proposed complementary approach to vein stabilization within this evolving healthcare environment.
Licensing Opportunity
Vein Guardian is available for licensing consideration by medical device manufacturers, healthcare product companies, and organizations interested in developing innovative vascular access technologies.
Interested parties are encouraged to explore the invention and its potential commercial applications.
To view the Vein Guardian marketing video and discover additional patented inventions, visit:
https://123axis.com/videos/
About Axis International Marketing
Axis International Marketing works with inventors to introduce patented products and innovative concepts to prospective manufacturers, buyers, and licensing partners. Through marketing presentations, product videos, and commercial outreach, Axis helps connect inventions with potential opportunities for commercialization.
Vein Guardian is presented as a patented concept. Product illustrations are concept visualizations, and the device's clinical performance, safety, and regulatory status have not been independently established in this release.
Vein Guardian incorporates two opposing C-arc magnets positioned along either side of a target vein. The same-polarity magnets are intended to create a repulsive magnetic field that helps stabilize the vein while maintaining an open center for visibility and needle access.
The invention is designed to operate without batteries, charging, or external power. Its adjustable straps and reusable configuration are intended to provide a practical, compact solution for a variety of potential healthcare applications.
Designed for Home and Clinical Applications
As healthcare delivery continues to expand beyond traditional clinical environments, medical device developers are exploring technologies that may support greater patient independence and simplify certain procedures.
Vein Guardian is intended for potential applications involving home self-injection, hospital and clinical IV access, and blood collection in laboratory settings.
The invention's open-center design is intended to allow healthcare professionals and appropriately trained users to locate and access the target vein without removing the device.
A Growing Healthcare Market
According to Mordor Intelligence, the global injectable drug delivery devices market is projected to grow from approximately $810 billion in 2026 to $1.20 trillion by 2031. This broader market includes a wide range of injection technologies and reflects growing interest in home-based healthcare and self-administration.
Vein Guardian represents a proposed complementary approach to vein stabilization within this evolving healthcare environment.
Licensing Opportunity
Vein Guardian is available for licensing consideration by medical device manufacturers, healthcare product companies, and organizations interested in developing innovative vascular access technologies.
Interested parties are encouraged to explore the invention and its potential commercial applications.
To view the Vein Guardian marketing video and discover additional patented inventions, visit:
https://123axis.com/videos/
About Axis International Marketing
Axis International Marketing works with inventors to introduce patented products and innovative concepts to prospective manufacturers, buyers, and licensing partners. Through marketing presentations, product videos, and commercial outreach, Axis helps connect inventions with potential opportunities for commercialization.
Vein Guardian is presented as a patented concept. Product illustrations are concept visualizations, and the device's clinical performance, safety, and regulatory status have not been independently established in this release.
Source: Axis International Marketing
0 Comments
Latest on PrZen
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
- Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
- PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
- KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
- Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
